Brief: Abbvie Qtrly Adj EPS $2.79 Vs LSEG IBES Estimate $2.77

Cerevel Therapeutics Holdings

02/02/2024 12:36

Feb 2 (Reuters) - Abbvie Inc  ABBV.N :
    * ABBVIE QTRLY ADJUSTED EARNINGS PER SHARE $2.79 VERSUS LSEG
IBES
ESTIMATE $2.77
    * ABBVIE QTRLY WORLDWIDE NET REVENUE $14.30 BILLION VERSUS
LSEG
IBES ESTIMATE $14.02 BILLION
    * ABBVIE QTRLY EARNINGS PER SHARE $0.46
    * FY2024 EARNINGS PER SHARE VIEW $11.24 -- LSEG IBES DATA
    * ABBVIE SEES 2024 ADJUSTED EARNINGS PER SHARE $11.05 TO
$11.25
    * ABBVIE: REAFFIRMS VIEW FOR HIGH SINGLE-DIGIT COMPOUND
ANNUAL
REVENUE GROWTH RATE THROUGH 2029
    * ABBVIE: RAISES 2027 COMBINED SALES OUTLOOK FOR SKYRIZI &
RINVOQ
TO MORE THAN $27 BILLION
    * ABBVIE: RAISES PEAK SALES VIEW FOR UBRELVY & QULIPTA TO
MORE
THAN $3 BILLION COMBINED
    * ABBVIE QTRLY GLOBAL HUMIRA NET REVENUE $3.30 BILLION, DOWN
40.8%
    * ABBVIE: IMMUNOGEN & CEREVEL DEALS EXPECTED TO CLOSE IN
MID-2024
    * ABBVIE QTRLY GLOBAL SKYRIZI NET REVENUE $2.39 BILLION, UP
51.9%
    * ABBVIE: 2024 ADJUSTED EARNINGS PER SHARE VIEW INCLUDES
$0.32/SHARE DILUTIVE IMPACT FROM IMMUNOGEN & CEREVEL
THERAPEUTICS DEALS
    * ABBVIE QTRLY GLOBAL RINVOQ NET REVENUE $1.26 BILLION, UP
62.9%
    * ABBVIE: QTRLY RESULTS INCLUDE UNFAVORABLE IMPACT OF
$0.15/SHARE
FROM ACQUIRED IPR&D & MILESTONES EXPENSE

Source text for Eikon:  ID: 
Further company coverage:  ABBV.N 

 ((Reuters.Briefs@thomsonreuters.com;))